News | EP Mapping and Imaging Systems | October 15, 2019

Kardium Announces Successful Results From GLOBAL-AF Study

Patients treated with Globe electrophysiology mapping and ablation solution showed 76 percent freedom from atrial fibrillation at 12 months after single treatment

Kardium Announces Successful Results From GLOBAL-AF Study

October 15, 2019 — Kardium Inc. announced that the Globe mapping and ablation system has successfully demonstrated safety and efficacy in the GLOBAL-AF study. The results of the study were published in the Journal of Cardiovascular Electrophysiology.[1] The study demonstrated a 76 percent percent freedom from atrial fibrillation at 12 months after a single treatment with the Globe system.

“I am very excited about the results from this first clinical experience with the Globe system” said Prof. Hans Kottkamp, head of electrophysiology, Sana Hospitals, Düsseldorf, Germany, the principal investigator. “The Globe system has demonstrated the ability to provide rapid and effective pulmonary vein isolation. In addition, the ability to perform high-resolution mapping and ablation of the atrium will deliver a unique and comprehensive treatment for patients that has the potential to further improve outcomes and advance new strategies for the treatment of AF.”

The Globe system is a mapping and ablation solution that consists of a catheter with 122 electrodes and advanced software, that together enable rapid pulmonary vein isolation, high-resolution mapping and the ability to ablate anywhere in the atrium, all with a single catheter.

Atrial fibrillation is the most common heart rhythm disorder and affects about 33 million people worldwide. It can increase the risk of stroke by up to five times.

The GLOBAL-AF study is a prospective multicenter study that evaluated the safety and effectiveness of the system in 60 patients at two centers in Europe. Patients were assessed for atrial fibrillation with seven-day continuous Holter monitoring at discharge and then 3, 6 and 12 months after the treatment. Patients in the efficacy cohort had 100 percent pulmonary vein isolation and 76 percent freedom from atrial fibrillation at 12 months, off antiarrhythmic drugs, after a single procedure.

For more information: www.kardium.com

Reference

1. Kottkamp H., Hindricks G., Ponisch C., et al. Global multielectrode contact‐mapping plus ablation with a single catheter in patients with atrial fibrillation: Global AF study. Journal of Cardiovascular Electrophysiology, published online Sept. 11, 2019. https://doi.org/10.1111/jce.14172

Related Content

Frequent Drinking Greater Risk Factor for Heart Rhythm Disorder Than Binge Drinking

Image courtesy of the American Heart Association.

News | Atrial Fibrillation | October 22, 2019
October 22, 2019 —  Drinking small amounts of alcohol frequently is linked with a higher likelihood of...
Dr. Markus Krane, deputy director of the Cardiac and Vascular Surgery Unit at the DHM helped compile an atlas of the heart and discovered myosin binding protein H-like (MYBPHL) occurs only in the atria of the heart. Researchers began using it as a blood test biomarker to assess the success of atrial fibrillation ablation procedures.

Dr. Markus Krane, deputy director of the Cardiac and Vascular Surgery Unit at the DHM helped compile an atlas of the heart and discovered myosin binding protein H-like (MYBPHL) occurs only in the atria of the heart. Researchers began using it as a blood test biomarker to assess the success of atrial fibrillation ablation procedures.

Feature | Atrial Fibrillation | July 24, 2019
July 24, 2019 — Atrial fibrillation (AFib) is a common abnormal heart rhythm.
New Technology Improves Atrial Fibrillation Detection After Stroke
News | Atrial Fibrillation | July 19, 2019
A new method of evaluating irregular heartbeats outperformed the approach that’s currently used widely in stroke units...
An screen shot of the Abbott Focal Impulse and Rotor Modulated (FIRM)-guided ablation system used to guide AF ablation procedures.

An screen shot of the Abbott Focal Impulse and Rotor Modulated (FIRM)-guided ablation system used to guide AF ablation procedures. 

News | Atrial Fibrillation | May 14, 2019 | Dave Fornell, Editor
May 14, 2019 – The first prospective, multicenter, randomized, controlled trial to compare conventional pulmonary vei
The Parasym Salustim device ear clip stimulates the vagus nerve, which was found to reduced AF burden compared with a sham procedure in the TREAT AF trial.

The Parasym Salustim device ear clip stimulates the vagus nerve, which was found to reduced AF burden compared with a sham procedure in the TREAT AF trial. 

News | Atrial Fibrillation | May 13, 2019
May 13, 2019 — A randomized clinical trial effectively used nerve stimulation through an ear clip to reduce...
More than 60,000 from the general population in Belgium were screened for AFib using only a smartphone app in the DIGITAL-AF II study. The study used the FibriCheck app found 791 participants has measurements indicative for AF.

More than 60,000 from the general population in Belgium were screened for AFib using only a smartphone app in the DIGITAL-AF II study. The study used the FibriCheck app found 791 participants has measurements indicative for AF.

News | Atrial Fibrillation | May 13, 2019
May 13, 2019 — A digital screening for...
Overlay Init